Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Effects of blood collection conditions on ovarian cancer serum markers.

Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N.

PLoS One. 2007 Dec 5;2(12):e1281.

PMID:
18060075
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.

Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.

BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

PMID:
23551967
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

PMID:
19423517
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
[PubMed - indexed for MEDLINE]
5.

[Evaluation of selected serum protein markers as early detectors of ovarian cancer].

Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kołosza Z, Chmura A, Czernik E, Masłyk B, Bartnik W, Cnota W.

Ginekol Pol. 2008 Apr;79(4):271-5. Polish.

PMID:
18592865
[PubMed - indexed for MEDLINE]
6.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

PMID:
18258665
[PubMed - indexed for MEDLINE]
Free Article
7.

Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.

Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81. doi: 10.1158/1055-9965.EPI-08-0464.

PMID:
18843033
[PubMed - indexed for MEDLINE]
Free Article
8.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

PMID:
21372037
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

PMID:
15734951
[PubMed - indexed for MEDLINE]
Free Article
10.

Combination of serum biomarkers to differentiate malignant from benign ovarian tumours.

He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, Mes-Masson AM, Provencher D, Gotlieb WH.

J Obstet Gynaecol Can. 2012 Jun;34(6):567-74.

PMID:
22673173
[PubMed - indexed for MEDLINE]
11.

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr.

Gynecol Oncol. 2007 Dec;107(3):526-31. Epub 2007 Oct 24.

PMID:
17920110
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.

J Clin Oncol. 2007 Apr 10;25(11):1383-9.

PMID:
17416858
[PubMed - indexed for MEDLINE]
13.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.

Clin Cancer Res. 2007 Dec 15;13(24):7370-9.

PMID:
18094419
[PubMed - indexed for MEDLINE]
Free Article
14.

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.

PMID:
17490732
[PubMed - indexed for MEDLINE]
15.

Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.

Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1127-33. doi: 10.1158/1055-9965.EPI-08-0653. Epub 2009 Mar 31.

PMID:
19336561
[PubMed - indexed for MEDLINE]
Free Article
16.

High serum levels of follistatin in patients with ovarian cancer.

Ren P, Chen FF, Liu HY, Cui XL, Sun Y, Guan JL, Liu ZH, Liu JG, Wang YN.

J Int Med Res. 2012;40(3):877-86.

PMID:
22906260
[PubMed - indexed for MEDLINE]
17.

Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.

Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE.

Proteomics. 2005 Nov;5(17):4625-36.

PMID:
16220531
[PubMed - indexed for MEDLINE]
18.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

PMID:
20593939
[PubMed - indexed for MEDLINE]
Free Article
19.

Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G.

JAMA. 1998 Aug 26;280(8):719-23.

PMID:
9728644
[PubMed - indexed for MEDLINE]
20.

Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.

McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8.

PMID:
17671125
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk